UBS Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $705.00

United Therapeutics (NASDAQ:UTHR) had its target price hoisted by analysts at UBS Group from $655.00 to $705.00 in a research report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the biotechnology company’s stock. UBS Group’s target price indicates a potential upside of 47.44% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on UTHR. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Bank of America reiterated a “neutral” rating on shares of United Therapeutics in a research report on Wednesday, February 25th. Royal Bank Of Canada raised their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. HC Wainwright boosted their price target on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, TD Cowen upped their price objective on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $539.00.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $478.16 on Thursday. The stock has a market capitalization of $20.96 billion, a P/E ratio of 17.14, a PEG ratio of 1.75 and a beta of 0.84. The business has a 50 day simple moving average of $482.51 and a two-hundred day simple moving average of $452.28. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $537.19.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the previous year, the company posted $6.19 earnings per share. The business’s revenue was up 7.4% on a year-over-year basis. As a group, research analysts anticipate that United Therapeutics will post 24.48 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 21,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $478.60, for a total transaction of $10,050,600.00. Following the completion of the sale, the chief financial officer directly owned 8,142 shares in the company, valued at approximately $3,896,761.20. This trade represents a 72.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 377,184 shares of company stock worth $183,015,947. Insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of UTHR. Torren Management LLC acquired a new stake in shares of United Therapeutics during the 4th quarter worth approximately $26,000. Activest Wealth Management lifted its holdings in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. WealthCollab LLC grew its position in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. grew its position in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in United Therapeutics during the fourth quarter worth $31,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: UBS raised its price target on UTHR from $655 to $705 and kept a Buy rating — a notable analyst endorsement implying material upside that could attract buyers. Read More.
• Neutral Sentiment: Multiple sell‑side firms have recently increased targets and reiterated Buy/outperform views (Oppenheimer, HC Wainwright, TD Cowen); consensus remains a “Moderate Buy” with a mid‑range price target, supporting a constructive medium‑term thesis. Read More.
• Negative Sentiment: A wave of insider selling this week is pressuring sentiment: CEO Martine Rothblatt sold 9,500 shares (~$4.65M), and several directors/executives (Ray Kurzweil, Paul Mahon, Tommy G. Thompson and others) also sold blocks at roughly $483–$490 per share. These large, concentrated disposals can prompt near‑term weakness even if insiders retain stakes. Read More. Read More.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.